Connect
MJA
MJA

Directions for clinical practice improvement in HFE gene mutation testing

Melissa J Gillett, Cyril D Mamotte, David Ravine and Samuel D Vasikaran
Med J Aust 2007; 187 (6): 342-344.
Published online: 17 September 2007

A number of inherited and acquired disorders may result in iron overload; hereditary haemochromatosis (HH) is the most frequent in populations of northern European descent. HH was previously regarded as a distinct clinical entity with a single genetic aetiology. The discovery of HH-causative mutations in the HFE gene1 revealed that both these assumptions were wrong.

HH is usually associated with homozygosity for the C282Y mutation in the HFE gene.2 However, one in eight healthy Australians are heterozygous carriers of C282Y3 and one in four are carriers of an H63D mutation,4 which must be considered when interpreting HFE genotype results in patients with iron overload. Although homozygosity for the C282Y mutation was thought to predispose people to severe organ damage from excessive iron accumulation, a number of studies have shown that only in a minority of cases do people develop severe clinical disease or organ damage.3,5-9

From a clinical perspective, it is now evident that HFE mutations are not responsible for all cases of HH; other genes contributing to iron homeostasis have been identified,2 although homozygosity for C282Y predominates among Australian HH patients, most of whom have western European ancestry.10

Biochemical testing for iron overload and genetic testing for HFE status are handled differently. The former will confirm or rule out current iron overload, while HFE testing, depending on the prior risk, will give a post-test probability of the patient developing iron overload. Clinical interpretation of HFE genotypes found in patients being investigated for iron overload and interpretation of HFE results in healthy first-degree relatives of a newly diagnosed patient can therefore vary substantially.

In our laboratory, we seek to offer appropriate guidance by including interpretive comments with our HFE genotype test results. However, in the absence of clinical details on the request form (a not uncommon occurrence) and relevant biochemical details, this is not always possible. With the objective of improving the quality of our HFE genotype reports, we retrospectively audited the clinical indications for a consecutive series of requests.

Methods

We reviewed all requests for HFE genotyping received by the Biochemical Genetics Laboratory at Royal Perth Hospital (RPH) over a 25-month period (June 2003 – June 2005). The audit was registered with the Quality Unit in the RPH Division of Laboratory Medicine. Samples were forwarded either by doctors within RPH or from doctors (predominantly general practitioners) external to the hospital. When the clinical reason for the test had not been provided, the notes of hospital cases were reviewed, and external referring doctors were contacted directly.

Reasons prompting the requests for HFE genotyping were then audited for compliance with the indications specified in the Australian Medicare Benefits Schedule (MBS),11 which are:

  • elevated transferrin saturation or serum ferritin level on testing of repeated specimens;

  • a first-degree relative with haemochromatosis; or

  • a first-degree relative with homozygosity for the C282Y mutation or compound heterozygosity for recognised genetic mutations associated with raised susceptibility to iron overload.

Results

We reviewed 105 requests from doctors within RPH and 82 requests from external doctors. Seventy of the 187 requests (37%) did not have sufficient accompanying clinical details to permit inclusion of a suitable interpretive comment with the result. Relevant details could not be retrospectively ascertained for seven of the 82 external requests. Re-evaluation of the remaining 180 requests after missing clinical details had been collated revealed that 103 (57%) were made for reasons outside the defined criteria for genotyping (Box). These included: problems possibly attributable to iron overload (ie, arthritis, diabetes, cardiomyopathy, porphyria cutanea tarda and hypogonadism), but without biochemical confirmation of iron overload; abnormal liver function test results, again in the absence of evidence of iron overload; the discovery of an isolated increase in serum ferritin; or having an HH-affected partner or kin more distant than a first-degree relationship.

Discussion

Good clinical laboratory practice extends to the interpretation of raw data,12 which is difficult in the absence of clinical details. This is true for the interpretation of HFE genotype results and for offering guidance about the significance of the results for first-degree relatives. Previously reported experience with integrating clinical indications for HFE testing with genotype results has revealed the high utility of HFE test results for patients in whom testing is clinically justifiable.13 As a prelude to integrating prior-risk data obtained from clinical details into HFE genotype reports, we retrospectively audited the clinical rationale for a consecutive series of samples forwarded for testing to our pathology service. Unexpectedly, we found that more than half the requests were for reasons not specified in the Australian MBS guidelines.11

This audit finding reveals that our laboratory’s current practice of accepting and testing all samples forwarded for HFE genotyping is suboptimal. As well as receiving samples without accompanying clinical details, we encountered requests to genotype samples from patients suspected to have HH, but without biochemical confirmation of excessive body iron stores. A small proportion of requests received were for samples forwarded from distant relatives and healthy partners of HH-affected people.

Although not included in the MBS-defined indications, HFE testing of partners of HH-affected people has been demonstrated to be a cost-effective investigation that frequently eliminates the need for testing of children.14 Our findings prompted us to consider both the validity of the indications defined in the MBS for HFE testing and the laboratory’s expectation that clinicians fully appreciate the clinical utility and limitations of HFE genotype tests that they order. Comparison of the Australian MBS guidelines for HFE genotyping with the recommended guidelines in the United States15 and United Kingdom,16 which are also formulated for populations that originate predominantly from western Europe where HFE mutations are responsible for over 90% of HH, reveals a consistent approach across these jurisdictions.

Our findings complement a recent Dutch study, which evaluated the impact of a clinical guideline for targeted early detection and treatment of HH aided by HFE gene mutation testing and found that one in five HFE gene mutation test results had been interpreted incorrectly.17 This is perhaps not surprising, particularly as HH is a relatively uncommon disorder, and only a minority of clinicians will have broad experience with the practical issues surrounding diagnosis in an index case and follow-up of high-risk first-degree relatives. To add to this difficulty, new information continues to emerge about the clinical significance of HFE mutations.18

These findings suggest a need for ongoing postgraduate education on the practical utility of genetic testing for HH, bearing in mind the differing needs of hospital specialists and GPs who serve patients with very different illness patterns. Our results support the findings of a survey of over 2500 American physicians, which concluded that many physicians have inadequate knowledge about haemochromatosis diagnosis.19 A physician education program on detection and management of HH in the US resulted in earlier case detection and treatment of iron overload.20

The key question is how best to deliver the required education, particularly in the Australian context of an MBS-listed genetic test. A physician survey of an innovative laboratory medicine interpretive service at Massachusetts General Hospital in Boston,21 which integrates clinical details and other relevant test results into the interpretation, revealed a high level of physician satisfaction with the service. The laboratory interpretive service involved a daily sign-out round, with a pathologist and a trainee “resident” reviewing each case and integrating the laboratory results with relevant clinical details to provide a clinically relevant, patient-specific interpretation of each patient’s laboratory test results. A notable strength of the service was the delivery of test-ordering education to clinicians in the context of their daily workflow, which resulted in saved time and improvements to the diagnostic process. A similar approach to genetic testing for HH could be effective, particularly as a vehicle for targeted postgraduate education. The strategy could also be extended to include other genetic tests, where enhanced clinical care or reduced levels of inappropriate testing may be achieved by closer clinical laboratory liaison.

Some may question whether it is the laboratory’s role to add interpretive comments to reports, particularly those of gene mutation analysis. It is uncommon in clinical biochemistry for individualised interpretive comments to be included on reports such as liver function tests, urea and electrolyte profiles. The high volume of such tests, as well as the frequent lack of clinical details, usually precludes this.22 However, recent improvements in information technology are reducing the size of these barriers.23 For more specialised and recently introduced investigations, particularly genetic tests such as HFE genotyping, our findings reveal opportunities for health cost savings and clinical practice improvement that could be realised by targeted input at the critical points of assessing clinical indications for testing and preparing appropriate interpretive comments for genotype results.

Reasons for requesting HFE genotyping

Reason

Hospital requests

External requests

Total


Compliant with MBS indications

38

39

77

Elevated transferrin saturation or serum ferritin level on testing of repeated specimens

33

12

45

Family history (first-degree relative with either haemochromatosis or a C282Y mutation)

5

27

32


Not compliant with MBS indications

67

36

103

Abnormal liver function test results with unconfirmed biochemical evidence of iron overload

22

7

29

Abnormal liver function test results only

39

4

43

Unconfirmed biochemical evidence of iron overload only

2

13

15

Symptoms possibly attributable to iron overload in the absence of known iron or liver function test abnormalities

0

7

7

Affected partner or family history (not first-degree relative)

4

5

9

Unable to obtain patient details retrospectively

0

7

7

Total number of cases

105

82

187


MBS = Medicare Benefits Schedule.11

Received 13 December 2006, accepted 8 June 2007

  • Melissa J Gillett1
  • Cyril D Mamotte1,2
  • David Ravine1,3,4
  • Samuel D Vasikaran1,5

  • 1 PathWest-Royal Perth Hospital, Perth, WA.
  • 2 School of Biomedical Sciences, Curtin University of Technology, Perth, WA.
  • 3 Western Australian Institute for Medical Research, Centre for Medical Research, Perth, WA.
  • 4 School of Medicine and Pharmacology, University of Western Australia, Perth, WA.
  • 5 School of Surgery and Pathology, University of Western Australia, Perth, WA.


Acknowledgements: 

We appreciate the helpful input provided by Dr John Olynyk.

Competing interests:

None identified.

  • 1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
  • 2. Pietrangelo A. Hereditary hemochromatosis — a new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
  • 3. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
  • 4. Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122: 646-651.
  • 5. Rossi E, Kuek C, Beilby JP, et al. Expression of the HFE hemochromatosis gene in a community-based population of elderly women. J Gastroenterol Hepatol 2004; 19: 1150-1154.
  • 6. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
  • 7. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209-223.
  • 8. McCune CA, Ravine D, Carter K, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006; 55: 554-562.
  • 9. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-1535.
  • 10. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 249-251.
  • 11. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. 1 November 2004. Canberra: Commonwealth of Australia, 2004.
  • 12. Fraser CG, Fogarty Y. Interpreting laboratory results. BMJ 1989; 298: 1659-1660.
  • 13. Acton RT, Barton JC. HFE genotype frequencies in consecutive reference laboratory specimens: comparisons among referral sources and association with initial diagnosis. Genet Test 2001; 5: 299-306.
  • 14. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132: 261-269.
  • 15. Qaseem A, Aronson M, Fitterman N, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143: 517-521.
  • 16. Dooley J, Worwood M; Clinical Task Force of the British Committee for Standards in Haematology. Guidelines on diagnosis and therapy: genetic haemochromatosis. Abingdon, UK: Darwin Medical Communications Ltd, 2000. http://www.bcshguidelines.com/pdf/chpt9B.pdf (accessed Jul 2007).
  • 17. Jacobs EM, Meulendijks CF, Elving L, et al. Impact of the introduction of a guideline on the targeted detection of hereditary haemochromatosis. Neth J Med 2005; 63: 205-214.
  • 18. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4: 1403-1410.
  • 19. Acton RT, Barton JC, Casebeer L, Talley L. Survey of physician knowledge about hemochromatosis. Genet Med 2002; 4: 136-141.
  • 20. Hover AR, McDonnell SM, Burke W. Changing the clinical management of hereditary hemochromatosis: translating screening and early case detection strategies into clinical practice. Arch Intern Med 2004; 164: 957-961.
  • 21. Laposata ME, Laposata M, Van Cott EM, et al. Physician survey of a laboratory medicine interpretive service and evaluation of the influence of interpretations on laboratory test ordering. Arch Pathol Lab Med 2004; 128: 1424-1427.
  • 22. Prinsloo PJ, Gray TA. A survey of laboratory practice in the clinical authorization and reporting of results. Ann Clin Biochem 2003; 40: 149-155.
  • 23. McNeely MD. The use of expert systems for improving test use and enhancing the accuracy of diagnosis. Clin Lab Med 2002; 22: 515-528.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.